Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
PLX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
CERNCerner Corporation
-0.47%56.697.6%$122.41m
DGXQuest Diagnostics Incorporated
-0.89%88.454.3%$121.04m
LHLaboratory Corporation of America Holdings
-0.91%152.922.3%$96.35m
SRCLStericycle, Inc.
2.44%51.726.3%$63.65m
HCSGHealthcare Services Group, Inc.
1.15%32.516.7%$52.57m
OMCLOmnicell, Inc.
-0.28%79.7510.6%$29.56m
MDRXAllscripts Healthcare Solutions, Inc.
0.10%9.919.9%$25.56m
HMSYHMS Holdings Corp.
0.07%30.901.9%$22.36m
CPSIComputer Programs and Systems, Inc.
0.50%29.9932.9%$4.09m
HSTMHealthStream, Inc.
0.50%27.996.7%$3.70m
PMDPsychemedics Corporation
-4.53%14.550.7%$0.49m
PLXProtalix Biotherapeutics, Inc.
-10.65%0.415.8%$0.23m
IDXGInterpace Diagnostics Group, Inc.
-0.98%0.843.3%$0.22m
BASIBioanalytical Systems, Inc.
0.00%2.000.3%$0.05m
STRMStreamline Health Solutions, Inc.
-8.70%1.050.3%$0.01m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.